Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19

• DOI: 10.1101/2023.08.29.23293790
• Publication Date: 2023-08-31T23:45:14Z
• Authors: Juan G. Ripoll; Sidna M. Tulledge...; Anthony A. Stephe...; Shane Ford; Marsha L. Pike; Ellen K. Gorman; Sara N. Hanson; Justin E. Juskewitch; Alex J. Miller; Solomiia Zaremba; Erik A. Ovrom; Raymund R. Razonable; Ravindra Ganesh; Ryan T. Hurt; Erin N. Fischer; Amber N. Derr; Michele R. Eberle; Jennifer J. Larsen; Christina M. Carney; Elitza S. Theel; Sameer A. Parikh; Neil E. Kay; Michael J. Joyner; Jonathon W. Senefeld
• Keywords: Immunosuppression; Concomitant; Convalescent plasma

ABSTRACT Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients immunosuppression have poor immunogenic responses to vaccines remain at high risk of infection SARS-CoV-2 hospitalization. Additionally, monoclonal antibody therapy is limited by the emergence novel variants that serially escaped neutralization. In this context, there interest in understanding clinical benefit convalescent plasma collected from persons who been both naturally infected vaccinated against (“vax-plasma”). Thus, we report outcome 386 immunocompromised outpatients were diagnosed received contemporary specific therapeutics (standard care group) a subgroup also concomitant treatment very titer (vax-plasma focus on rates. The overall rate was 2.2% (5 225 patients) vax-plasma group 6.2% (10 161 standard group, which corresponded relative reduction 65% ( P =0.046). Evidence efficacy nonvaccinated cannot be inferred these data because 94% (361 vaccinated. COVID-19, addition or therapies reduced progression leading IMPORTANCE As evolves, new concern (VOCs) emerged evade available anti-spike antibodies, particularly immunosuppressed patients. However, high-titer continues effective VOCs its broad-spectrum immunomodulatory properties. outcomes treated vaccine-boosted plasma. We found administration significantly decreased incidence outpatients. Our add providing evidence support utility as replacement